Clinical Trial Update: A Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of rituximab (MabThera/Rituxan) in follicular lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Rituximab (Rituxan/MabThera) (rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED